Illumina (ILMN) to Announce Quarterly Earnings on Thursday

Illumina (NASDAQ:ILMN) is anticipated to release its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to announce earnings of $1.23 per share and revenue of $1.1306 billion for the quarter. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period last year, the company earned $0.97 earnings per share. On average, analysts expect Illumina to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Illumina Price Performance

Shares of ILMN opened at $190.87 on Thursday. Illumina has a one year low of $88.00 and a one year high of $196.66. The stock’s fifty day moving average is $169.14 and its 200-day moving average is $144.62. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. The firm has a market capitalization of $28.88 billion, a price-to-earnings ratio of 34.70, a price-to-earnings-growth ratio of 2.84 and a beta of 1.47.

Insider Transactions at Illumina

In other Illumina news, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $180.00, for a total transaction of $110,700.00. Following the sale, the insider owned 20,953 shares in the company, valued at approximately $3,771,540. The trade was a 2.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $162.59, for a total transaction of $127,307.97. Following the sale, the senior vice president directly owned 21,259 shares of the company’s stock, valued at $3,456,500.81. This represents a 3.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,003,769 shares of company stock worth $155,710,908 in the last three months. Insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Illumina

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ILMN. Quarry LP purchased a new position in Illumina during the 3rd quarter worth approximately $32,000. Brown Brothers Harriman & Co. raised its stake in Illumina by 975.6% during the 4th quarter. Brown Brothers Harriman & Co. now owns 441 shares of the life sciences company’s stock valued at $58,000 after purchasing an additional 400 shares during the period. Itau Unibanco Holding S.A. lifted its holdings in shares of Illumina by 93.1% in the fourth quarter. Itau Unibanco Holding S.A. now owns 556 shares of the life sciences company’s stock valued at $73,000 after purchasing an additional 268 shares in the last quarter. Advisory Services Network LLC purchased a new stake in shares of Illumina in the third quarter valued at $102,000. Finally, Headlands Technologies LLC acquired a new stake in shares of Illumina in the second quarter worth $165,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Sanford C. Bernstein assumed coverage on Illumina in a research report on Friday, June 26th. They issued a “market perform” rating and a $185.00 target price for the company. Evercore restated an “outperform” rating on shares of Illumina in a report on Monday, July 6th. Weiss Ratings raised Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Guggenheim lifted their target price on Illumina from $180.00 to $200.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Finally, Leerink Partners boosted their price target on shares of Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a research report on Friday, July 17th. Nine investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Illumina has a consensus rating of “Hold” and a consensus target price of $156.88.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.